Humanized mouse models for preclinical evaluation of HIV cure strategies.
Humanized mouse models for preclinical evaluation of HIV cure strategies.
复制标题
DOI:
10.24875/aidsrev.22000013
复制
发表时间:
2022-10-25
期刊:
影响因子:
2.2
通讯作者:
Heredia, Alonso
中科院分区:
文献类型:
--
作者:
Fraker, Sally;Atkinson, Benjamin;Heredia, Alonso
Although the world is currently focused on the COVID-19 pandemic, HIV/AIDS remains a significant threat to public health. To date, the HIV/AIDS pandemic has claimed the lives of over 36 million people, while nearly 38 million people are currently living with the disease. Despite the undeniable success of antiretroviral therapy (ART) in controlling HIV, the medications are not curative. Soon after initial infection, HIV integrates into the genome as a provirus, primarily, within CD4+ T cells and tissue macrophages. When not actively transcribed, the provirus is hidden to the immune system and ART, and is referred to as a latent reservoir. Following ART discontinuation, HIV may emerge from the replication-competent proviruses and resumes the infection of healthy cells. Thus, these latent reservoirs are a major obstacle to an HIV cure, and their removal remains a priority. A vital aspect in the development of curative therapies is the demonstration of efficacy in an animal model, such as the humanized mouse model. Therefore, optimization, standardization, and validation of the humanized mouse model is a priority. The purpose of this review article is to provide an update on existing humanized mouse models, highlighting the advantages and disadvantages of each as they pertain to HIV cure studies, and to review the approaches to curative therapies that are under investigation.